Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday.
Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Chardan Capital restated a “buy” rating and set a $5.00 price objective (up from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.
Get Our Latest Stock Analysis on Arbutus Biopharma
Arbutus Biopharma Price Performance
Institutional Investors Weigh In On Arbutus Biopharma
A number of institutional investors have recently added to or reduced their stakes in ABUS. Whitefort Capital Management LP raised its holdings in shares of Arbutus Biopharma by 2.9% in the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock worth $43,301,000 after buying an additional 373,949 shares in the last quarter. Vanguard Group Inc. raised its stake in Arbutus Biopharma by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock worth $29,367,000 after acquiring an additional 62,282 shares in the last quarter. Two Seas Capital LP raised its stake in Arbutus Biopharma by 4.2% during the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock worth $28,583,000 after acquiring an additional 353,568 shares in the last quarter. State Street Corp lifted its holdings in shares of Arbutus Biopharma by 50.2% during the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock valued at $16,967,000 after acquiring an additional 1,472,652 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Arbutus Biopharma by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company’s stock valued at $11,390,000 after purchasing an additional 33,536 shares in the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Articles
- Five stocks we like better than Arbutus Biopharma
- What is the Dogs of the Dow Strategy? Overview and Examples
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- What to Know About Investing in Penny Stocks
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Options Trading – Understanding Strike Price
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.